科大訊飛(002230.SZ)年報:2020年營收超130億元、淨利潤增長66.48%
格隆匯 4 月 19日丨科大訊飛(002230.SZ)發佈2020年年度報吿,實現營業收入超過130億元,同比增長29.23%,其中,重點賽道智慧教育、智慧醫療業務分別實現70.68%和69.25%的增長;毛利58.76億元,同比增長26.69%;公司人均效能持續提升,人均毛利較前兩年實現了48%的提升;
歸屬於上市公司股東的淨利潤13.64億元,在助力疫情防控及社會捐贈等支出增加的情況下,淨利潤較去年同期增長66.48%;基本每股收益0.64元,擬每10股派發現金紅利2元(含税)。
實現經營活動產生的現金流量淨額22.71億元,再創歷史最好水平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.